Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.
Taofeek Kunle OwonikokoGuojing ZhangHyun S KimRenea M StinsonRabih BecharaChao ZhangZhengjia ChenNabil F SabaSuchita PakkalaRathi PillaiXingming DengShi-Yong SunMichael R RossiGabriel L SicaSuresh S RamalingamFadlo R KhuriPublished in: Journal of translational medicine (2016)
Cisplatin inhibited growth of PDX derived from platinum-sensitive SCLC but was ineffective against PDX from platinum-refractory SCLC. Strong concordance between clinical and ex vivo effects of ASO and cisplatin in SCLC supports the use of PDX models to prescreen promising anticancer agents prior to clinical testing in SCLC patients. Trial Registration The study was registered at http://www.clinicaltrials.gov (NCT01470248).
Keyphrases
- phase ii
- clinical trial
- small cell lung cancer
- open label
- phase iii
- end stage renal disease
- newly diagnosed
- ejection fraction
- double blind
- study protocol
- peritoneal dialysis
- chronic kidney disease
- acute lymphoblastic leukemia
- prognostic factors
- heavy metals
- acute myeloid leukemia
- drinking water
- randomized controlled trial
- diffuse large b cell lymphoma
- brain metastases
- multiple myeloma
- hodgkin lymphoma
- patient reported outcomes